InMed (NASDAQ: INM) outlines details for 2025 annual shareholder meeting

(Moderate)

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. reported that on September 23, 2025 it announced the meeting date, record date and related details for its 2025 annual meeting of shareholders through a filing on Canada’s SEDAR system. The company is making that SEDAR disclosure available to U.S. investors as Exhibit 99.1 to this report.

The company states that the information in this report, including Exhibits 99.1 and 99.2, is being furnished rather than filed under the U.S. securities laws, which limits how it is treated for liability purposes and incorporation by reference into other securities filings.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Accepted by SEC EDGAR 09/23/2025 - 05:11 PM

FAQ

What did InMed Pharmaceuticals (INM) disclose in this 8-K?

InMed Pharmaceuticals Inc. disclosed that it announced the meeting date, record date and certain other information for its 2025 annual meeting of shareholders via a SEDAR filing in Canada, and furnished that disclosure as Exhibit 99.1.

How is the 2025 annual shareholder meeting information for INM being shared with investors?

The information about InMed Pharmaceuticals’ 2025 annual shareholder meeting is contained in a SEDAR filing submitted on September 23, 2025, which the company has furnished to U.S. investors as Exhibit 99.1 to this report.

Are the InMed Pharmaceuticals exhibits considered filed or furnished?

InMed Pharmaceuticals states that the information in this report, including Exhibits 99.1 and 99.2, is being furnished and not filed under the Securities Exchange Act of 1934.

Does this InMed (INM) update affect its financial statements?

No financial statements or financial data are included in this update; it focuses on providing the meeting and record date information for the 2025 annual meeting of shareholders and furnishing related exhibits.

What is Exhibit 99.1 in InMed Pharmaceuticals’ 8-K?

Exhibit 99.1 is described as the SEDAR filing submitted on September 23, 2025 that contains details about InMed Pharmaceuticals’ 2025 annual meeting of shareholders.

Can the information in this InMed 8-K be automatically used in other securities filings?

InMed Pharmaceuticals notes that the information in this report, including Exhibit 99.1, will not be incorporated by reference into other Securities Act or Exchange Act filings unless specifically referenced there.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 23, 2025

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

British Columbia		001-39685		98-1428279
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

InMed Pharmaceuticals Inc. Suite 1445 - 885 W. Georgia Street, Vancouver, B.C. Canada		V6C 3E8
(Address of Principal Executive Offices)		(Zip Code)

Company’s telephone number, including area code: (604) 669-7207

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, no par value		INM		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On September 23, 2025, InMed Pharmaceuticals Inc. announced the meeting, record date and certain other information relating to its 2025 annual meeting of shareholders pursuant to a filing submitted to the System for Electronic Document Analysis and Retrieval (“SEDAR”) in Canada.

The information set forth in this Item 7.01, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

Exhibit No.		Description

99.1		SEDAR filing submitted September 23, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INMED PHARMACEUTICALS INC.

Date: September 23, 2025	By:	/s/ Eric A. Adams
		Eric A. Adams
		President and CEO

Source: View Original Filing on SEC EDGAR